Royal Fund Management LLC Acquires New Position in Eli Lilly And Co (NYSE:LLY)

Royal Fund Management LLC acquired a new stake in Eli Lilly And Co (NYSE:LLY) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 707 shares of the company’s stock, valued at approximately $98,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in LLY. Norges Bank purchased a new stake in shares of Eli Lilly And Co in the fourth quarter valued at about $1,171,509,000. Jennison Associates LLC grew its holdings in shares of Eli Lilly And Co by 125.9% in the first quarter. Jennison Associates LLC now owns 10,192,052 shares of the company’s stock valued at $1,413,841,000 after purchasing an additional 5,679,574 shares during the period. BlackRock Inc. grew its holdings in shares of Eli Lilly And Co by 5.6% in the first quarter. BlackRock Inc. now owns 64,299,477 shares of the company’s stock valued at $8,919,623,000 after purchasing an additional 3,420,265 shares during the period. Capital International Investors grew its holdings in shares of Eli Lilly And Co by 3.6% in the fourth quarter. Capital International Investors now owns 26,055,933 shares of the company’s stock valued at $3,424,531,000 after purchasing an additional 910,672 shares during the period. Finally, FMR LLC grew its holdings in shares of Eli Lilly And Co by 6.7% in the fourth quarter. FMR LLC now owns 14,235,227 shares of the company’s stock valued at $1,870,935,000 after purchasing an additional 888,413 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have weighed in on LLY. Barclays began coverage on shares of Eli Lilly And Co in a research note on Thursday, February 27th. They set an “overweight” rating for the company. Cowen increased their target price on shares of Eli Lilly And Co from $145.00 to $160.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. UBS Group lowered shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and increased their target price for the stock from $157.00 to $158.00 in a research note on Monday, April 20th. Mizuho increased their target price on shares of Eli Lilly And Co from $148.00 to $155.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Finally, Zacks Investment Research lowered their target price on shares of Eli Lilly And Co to $156.00 in a research note on Wednesday, April 29th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $158.64.

In related news, SVP Myles O’neill sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $140.15, for a total value of $3,503,750.00. Following the sale, the senior vice president now owns 44,773 shares of the company’s stock, valued at $6,274,935.95. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $139.11, for a total transaction of $29,213,100.00. Following the completion of the sale, the insider now directly owns 113,441,468 shares in the company, valued at approximately $15,780,842,613.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 906,320 shares of company stock worth $132,984,238. 0.09% of the stock is owned by corporate insiders.

NYSE LLY opened at $151.16 on Friday. The firm has a 50 day simple moving average of $152.85 and a 200-day simple moving average of $136.00. The company has a debt-to-equity ratio of 4.37, a quick ratio of 0.86 and a current ratio of 1.11. Eli Lilly And Co has a one year low of $101.36 and a one year high of $164.90. The firm has a market cap of $145.65 billion, a price-to-earnings ratio of 24.99, a PEG ratio of 1.82 and a beta of 0.25.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 23rd. The company reported $1.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.48 by $0.27. Eli Lilly And Co had a net margin of 23.97% and a return on equity of 194.18%. The business had revenue of $5.86 billion during the quarter, compared to analyst estimates of $5.48 billion. During the same quarter last year, the firm posted $1.33 earnings per share. The business’s revenue for the quarter was up 15.1% compared to the same quarter last year. Equities analysts predict that Eli Lilly And Co will post 6.81 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $0.74 dividend. The ex-dividend date is Thursday, May 14th. This represents a $2.96 annualized dividend and a yield of 1.96%. Eli Lilly And Co’s dividend payout ratio (DPR) is 49.01%.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Mutual funds are not immune from market timing

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.